Your contact persons

CHEPLAPHARM Arzneimittel GmbH

Changes of Management Board per April

CHEPLAPHARM is delighted to announce an addition to its board of management.

With effect of April 1st, 2021 Dr. Keyarasch “Kia” Parssanedjad, M.D. joins the company´s management board as Chief Corporate Investment Officer (CIO).

Dr. Parssanedjad is an entrepreneurial healthcare leader, who has more than 15 years of hands-on experience in both building, managing as well as investing into innovative, high-growth healthcare and life science businesses. 

Dr. Parssanedjad joins CHEPLAPHARM from McKinsey&Company, where he has been a co-leader of McKinsey’s global Leap practice in healthcare and life sciences focussing on business building with leading global clients. Previously, he held leadership roles at Merck Group. Dr. Parssanedjad is a trained physician and obtained his medical degree in the field of cancer research /gene therapy.

With this addition, CHEPLAPHARM further strengthens its management board by building on its core competence of corporate investments.

Back to topexpand_less